Neuromuscular Diseases Clinical Trial
— SAPPHIREOfficial title:
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
Verified date | May 2024 |
Source | Scholar Rock, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.
Status | Active, not recruiting |
Enrollment | 188 |
Est. completion date | December 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 21 Years |
Eligibility | Inclusion Criteria: - Males and females 2 through 21 years old at Screening. - Documented diagnosis of 5q SMA. - Diagnosed with later-onset SMA (i.e., Type 2 and Type 3 SMA) before receiving an approved SMN upregulator therapy (i.e., either nusinersen or risdiplam). - Must be Nonambulatory at Screening. Nonambulatory patients must be able to sit independently (sits up straight with head erect for at least 10 seconds; does not use arms or hands to balance body or support position) per World Health Organization (WHO) motor milestones definition at Screening. - Receiving one background therapy for SMA (i.e., either nusinersen or risdiplam) for the time period specified below and anticipated to remain on that same treatment throughout the trial: 1. If receiving the SMN upregulator therapy nusinersen, must have completed at least 10 months of dosing (i.e., completed the loading regimen and at least 2 maintenance doses) before Screening; 2. If receiving the SMN upregulator therapy risdiplam, must have completed at least 6 months of dosing before Screening. - Motor Function Score (HFMSE) =10 and =45 at Screening. - Have no physical limitations that would prevent the patient from undergoing motor function outcome measures throughout the duration of the study. - Able to receive study drug infusions and provide blood samples through the use of a peripheral intravenous (IV) or a long-term IV access device that the patient has placed for reasons independent from the study throughout the duration of the study. - Able to adhere to the requirements of the protocol, including travel to the study center and completing all study procedures and study visits. - For patients who are expected to have reached reproductive maturity by the end of the study, adhere to study specific contraception requirements. Exclusion Criteria: - Received ZOLGENSMA® (onasemnogene abeparvovec-xioi) at any time and previous treatment with apitegromab. - Use of invasive ventilation and tracheostomy. - Use of chronic daytime non-invasive ventilatory support for >16 hours daily in the 2 weeks prior to dosing, or anticipated to regularly receive such daytime ventilator support chronically over the duration of the study. - Any acute or co-morbid condition interfering with the well-being of the patient within 7 days of screening, including active systemic infection, the need for acute treatment or inpatient observation due to any reason. - Severe scoliosis and/or contractures at screening. Based on clinical judgement, any scoliosis or contractures present must be stable over the past 6 months, anticipated to be stable for the duration of the study and not prevent the patient from being evaluated on any functional outcome measures throughout the duration of the study. - Pregnant or breastfeeding. - Major orthopedic or other interventional procedure, including spine or hip surgery, considered to have the potential to substantially limit the ability of the patient to be evaluated on any functional outcome measures, within 6 months prior to Screening, or anticipated for the duration of the study. - Prior history of a hypersensitivity reaction to a monoclonal antibody (mAb) or recombinant protein bearing an Fc domain (such as a soluble receptor-Fc fusion protein), apitegromab, or excipients of apitegromab. - Treatment with investigational drugs within 3 months prior to Screening. - Use of therapies with potentially significant muscle effects (such as androgens, insulin-like growth factor, growth hormone, systemic beta-agonist, botulinum toxin, or muscle relaxants or muscle-enhancing supplements) or potentially significant neuromuscular effects (such as acetylcholinesterase inhibitors) within 60 days prior to screening. - Nutritional status not stable over the past 6 months and not anticipated to be stable throughout the duration of the study. - Patient has any other condition, which in the opinion of the Investigator may compromise safety or compliance, would preclude the patient from successful completion of the study, or interfere with the interpretation of the results. |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Gent | Gent | |
Belgium | UZ Leuven | Leuven | |
Belgium | Chr de La Citadelle | Liège | |
France | CHU Lille - Hôpital Jeanne de Flandre | Lille | |
France | Hôpital Armand Trousseau, I-Motion | Paris | |
France | CHU Toulouse - Hopital des Enfants | Toulouse | |
Germany | Universitätsklinikum Bonn | Bonn | |
Germany | Universitätsklinikum Essen | Essen | |
Germany | Universitaetsklinikum Freiburg | Freiburg | |
Germany | Dr. von Haunersches Kinderspital | Munich | |
Italy | IRCCS Istituto Giannina Gaslini | Genoa | |
Italy | A.O.U Policlinico G. Martino | Messina | |
Italy | ASST Grande Ospedale Metropolitano Niguarda | Milan | |
Italy | Foundation I.R.C.C.S. Carlo Besta Neurological Institute | Milan | |
Italy | Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Università Cattolica Sacro Cuore | Roma | |
Netherlands | Universitair Medisch Centrum Utrecht | Utrecht | |
Poland | Uniwersyteckie Centrum Kliniczne w Gdansku | Gdansk | |
Poland | Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu | Poznan | |
Poland | Instytut Pomnik - Centrum Zdrowia Dziecka: CZD Warszawa | Warsaw | |
Spain | Hospital Sant Joan de Déu | Barcelona | |
Spain | Hospital Universitario y Politécnico La Fe | Valencia | |
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds | |
United Kingdom | Great Ormond Street Hospital for Children NHS Foundation Trust | London | |
United Kingdom | University of Oxford | Oxford | |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | The Johns Hopkins University | Baltimore | Maryland |
United States | Children's of Alabama | Birmingham | Alabama |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Nationwide Children's Hospital | Columbus | Ohio |
United States | Children's Medical Center Dallas | Dallas | Texas |
United States | Helen DeVos Children's Hospital | Grand Rapids | Michigan |
United States | University of Iowa | Iowa City | Iowa |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Children's Hospital of Los Angeles | Los Angeles | California |
United States | University of Wisconsin School of Medicine and Public Health | Madison | Wisconsin |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Columbia University, SMA Clinical Research Center | New York | New York |
United States | Children's Hospital of The King's Daughters | Norfolk | Virginia |
United States | Nemours Children's Hospital | Orlando | Florida |
United States | Stanford University Medical Center | Palo Alto | California |
United States | Childrens Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | Oregon Health & Sciences University | Portland | Oregon |
United States | Washington University School of Medicine in St. Louis | Saint Louis | Missouri |
United States | Gillette Children's Specialty Healthcare | Saint Paul | Minnesota |
United States | University of Utah | Salt Lake City | Utah |
United States | Rady's Children's Hospital/UCSD | San Diego | California |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Wake Forest Baptist Medical Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Scholar Rock, Inc. |
United States, Belgium, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score. | The HFMSE assesses the physical abilities of patients with Type 2 and Type 3 SMA. It comprises of 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. | Baseline up to 12 months. | |
Secondary | Main Efficacy Population: Proportion of patients with =3-point change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score. | The HFMSE assesses the physical abilities of patients with Type 2 and Type 3 SMA. It comprises of 33 items graded on a scale of 0, 1, or 2, where 0 denotes unable, 1 denotes performed with modification or adaptation, and 2 denotes performed without modification or adaptation. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. | Baseline up to 12 months. | |
Secondary | Main Efficacy Population: Change from Baseline in Revised Upper Limb Module (RULM) total score. | The RULM is a 20 item assessment of upper limb function in nonambulatory patients with SMA that was performed for patients who were 30 months of age or older at baseline. The 19 scored items assess functions that relate to everyday life, such as pressing a button and picking up a token; these items are scored 0, 1, or 2, where 0 denotes unable, 1 denotes able with modification, and 2 denotes able with no modification. The maximum score achievable is 37. Higher scores increased great upper limb function. | Baseline up to 12 months. | |
Secondary | Main Efficacy Population: Change from Baseline in number of WHO motor development milestones attained at 12 months. | Baseline up to 12 months. | ||
Secondary | Main Efficacy Population and Exploratory Subpopulation combined: Incidence of Treatment Emergent Adverse Events (TEAEs) and Severe Adverse Events (SAEs) by severity. | Baseline up to 12 months. | ||
Secondary | Main Efficacy Population and Exploratory Subpopulation combined: Apitegromab concentrations in serum from blood samples. | Baseline up to 12 months. | ||
Secondary | Main Efficacy Population and Exploratory Subpopulation combined: Circulating latent myostatin concentrations in blood samples. | Baseline up to 12 months. | ||
Secondary | Main Efficacy Population and Exploratory Subpopulation combined: Presence or absence of ADA against apitegromab in serum from blood samples. | Baseline up to 12 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT04435093 -
Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.
|
||
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT05785546 -
Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System
|
||
Completed |
NCT01313325 -
Hippotherapy to Improve the Balance of Children With Movement Disorders
|
N/A | |
Recruiting |
NCT04098094 -
Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
|
||
Active, not recruiting |
NCT05070624 -
The Peer Support Study
|
N/A | |
Completed |
NCT04729920 -
Home Use of Mechanical Insufflation/Exsufflation Devices in Neuromuscular Diseases
|
||
Recruiting |
NCT04581577 -
Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
|
||
Completed |
NCT06428864 -
Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
|
||
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Completed |
NCT05353738 -
Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
|
||
Recruiting |
NCT04541602 -
Detection of Neuromuscular Complications in Critically Ill Patients
|
||
Completed |
NCT03394859 -
Electronic Medical Records and Genomics (eMERGE) Phase III
|
||
Enrolling by invitation |
NCT05099107 -
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment
|
N/A | |
Completed |
NCT05070910 -
NDT Effectiveness Study
|
N/A | |
Recruiting |
NCT04100993 -
Multisystem and Autonomic Complications of NMD on Long-term NIV
|
||
Recruiting |
NCT04986059 -
Effects of Pre-event Massage on Muscle Activity
|
N/A | |
Completed |
NCT01022931 -
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
|
N/A | |
Terminated |
NCT03353064 -
Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure
|
N/A |